Who are Treatment 2 Ondansetron's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trintellix, Mirtazapine/SNRIs, Kytril inj.+Kytril tab., Dexamethasone + Ondansetron, Granisetron (Group G), ramosetron, ondansetron, dexamethasone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/treatment-2-ondansetron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Treatment 2 Ondansetron — Competitive Intelligence Brief

Treatment 2 Ondansetron (Treatment 2 Ondansetron) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT3 receptor antagonist. Area: Oncology, Gastroenterology.

marketed 5-HT3 receptor antagonist 5-HT3 receptor Oncology, Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Treatment 2 Ondansetron (Treatment 2 Ondansetron) — Hamad Medical Corporation. Ondansetron blocks serotonin (5-HT3) receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Treatment 2 Ondansetron TARGET	Treatment 2 Ondansetron	Hamad Medical Corporation	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Mirtazapine/SNRIs	Mirtazapine/SNRIs	Shanghai Mental Health Center	marketed	Tetracyclic antidepressant	Alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors
Kytril inj.+Kytril tab.	Kytril inj.+Kytril tab.	LG Life Sciences	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Dexamethasone + Ondansetron	Dexamethasone + Ondansetron	University of Catania	marketed	Corticosteroid + 5-HT3 antagonist combination	Glucocorticoid receptor; 5-HT3 receptor
Granisetron (Group G)	Granisetron (Group G)	University of Malaya	marketed	5-HT3 receptor antagonist	5-HT3 receptor
ramosetron, ondansetron, dexamethasone	ramosetron, ondansetron, dexamethasone	Government Medical College, Haldwani	marketed	5-HT3 receptor antagonist + corticosteroid combination	5-HT3 receptor (ramosetron, ondansetron); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT3 receptor antagonist class)

Helsinn Healthcare SA · 4 drugs in this class
LG Life Sciences · 3 drugs in this class
University of Malaya · 2 drugs in this class
GlaxoSmithKline · 1 drug in this class
Hamad Medical Corporation · 1 drug in this class
Eye & ENT Hospital of Fudan University · 1 drug in this class
Instituto Mexicano del Seguro Social · 1 drug in this class
Chongqing University Cancer Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
MonoSol Rx · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Treatment 2 Ondansetron — Competitive Intelligence Brief. https://druglandscape.com/ci/treatment-2-ondansetron. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab